Navigation Links
Will the FDA Ban Hydroquinone in Pigment Control Products?
Date:9/8/2009

WALTHAM, Mass., Sept. 8 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the US market for physician-dispensed cosmeceutical pigment control products will experience considerable growth in sales over the next five years. MRG's US Markets for Physician-Dispensed Cosmeceuticals 2009 report finds, however, that product safety issues involving hydroquinone, the active ingredient in many pigment control products, have led the Food and Drug Administration (FDA) to second guess the use of the compound in such products.

Pigment control products are designed to reduce hyperpigmentation of the skin, including sun and age spots, scars, and acne discolorations, along with other skin conditions that cause uneven pigmentation. In 2006, the FDA proposed a ban on over-the-counter sales of hydroquinone products due to studies in rodents that indicated that hydroquinone may act as a carcinogen. Three years later, the FDA continues to review comments on the proposed ban but has yet to make a final ruling. Over-the-counter products containing 2% hydroquinone or less are still sold in the retail market, while products containing up to 4% hydroquinone are available by prescription only. The FDA plans to make a final ruling by the end of the year.

The uncertainty surrounding hydroquinone-based products has prompted some companies to explore the use of other skin lightening ingredients that are safer but yield similar aesthetic results. Additionally, some physicians have refrained from recommending hydroquinone products to their patients. Although the compound has been shown to be highly effective in skin lightening applications, concerns over product safety linger. If the FDA were to enforce a ban, all existing products in the market would require FDA approval before being sold and all products would be available by prescription only.

"If new pigment control products were able to generate fast, effective results without the use of hydroquinone, the pigment control market would experience tremendous growth," says Kevin Flewwelling, Manager of the Aesthetics division at MRG. "Although we don't think the FDA will ban the use of over-the-counter hydroquinone-based products, we expect that companies will continue to invest in the research and development of new, non-hydroquinone pigment control products because of the tremendous market opportunity."

About Report

MRG's US Markets for Physician-Dispensed Cosmeceuticals 2009 report covers the markets for physician-dispensed moisturizers, antiaging products, eye treatment products, cleansers and toners, pigment control products, acne treatments, sunscreens, and chemical peels in the US. The report provides unit sales and market revenues by product segment, including five-year forecasts, in-depth qualitative insights on leading products, and an analysis of the competitive landscape in each segment.

Webinar

Members of the media are welcome to attend our upcoming webinar entitled Shifting Dynamics in the Physician-Dispensed Cosmeceuticals and Facial Aesthetics Markets. This webinar will be held on Wednesday, September 23, 2009 at 11 a.m. U.S. Eastern Time. For more information, please contact Roisin Bonner at 416-364-7776 ext. 147 or by email at rbonner@mrg.net

About Millennium Research Group

Millennium Research Group (www.MRG.net), a Decision Resources, Inc. company (www.DecisionResourcesInc.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the health care sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack(TM) projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the health care industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Amy Krohn
    Millennium Research Group
    416-364-7776 x101
    akrohn@mrg.net

    Elizabeth Marshall
    Decision Resources Inc.
    781-296-2563
    emarshall@dresources.com


'/>"/>
SOURCE Millennium Research Group
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Photos: Lumixyl(TM) Enters the Market to Improve the Appearance of Hyperpigmentation without Irritation and Side Effects
2. Dermatologists Shed Light on Common Pigmentation Problems and Solutions in Skin of Color
3. Zebrafish Journal Publishes Skin Pigmentation Studies That Shed Light on the Evolution of Race
4. Cynosures Accolade(TM) Workstation for Pigmented Lesions Receives Korean Regulatory Approval
5. Neurotech Announces Completion of Enrollment of its Phase II/III Retinitis Pigmentosa and Phase II Dry Age Related Macular Degeneration Clinical Studies
6. Newly Published Clinical Study Finds New Commercial Diet Program Superior to Standard Protocol for Diabetes Weight Loss and Blood Sugar Control
7. Steven Saslona Named New Controller at Jackson & Coker
8. Moms-to-Be Need Facts on Pain Control
9. Pelosi: Public Option Best Way to Control Costs, Promote Competition
10. XLHealth Appoints New Controller to Lead Financial Compliance, Accounting Initiatives
11. Brain May Use Its Minds Eye to Control Chaos
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... 23, 2017 , ... On April 13, 2017, The ... “Doping in Sport: How the Culture Might Change,” in conjunction with Pepperdine ... will be held at Pepperdine University in Malibu, California. , Sir Philip Craven, ...
(Date:2/23/2017)... ... February 23, 2017 , ... ERT, ... trials, today announced that Premier Research, a leading clinical development service provider, has ... are becoming increasingly complex, due in part to an array of circumstances including ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Center ... Rhode Island Consortium for Autism Research and Treatment (RI-CART) and Cinemaworld to present ... spectrum disorder (ASD) to see films in an environment that accommodates their unique ...
(Date:2/23/2017)... ... February 23, 2017 , ... Top cosmetic and periodontal dentist ... today with a new Indiegogo campaign . Individuals are now able to contribute ... Los Angeles area, either as a participating patient or through an Indiegogo donation. The ...
(Date:2/23/2017)... ... February 23, 2017 , ... Thomas Vas-Don suffered from ... regime, the author was able to successfully recover. In “ Origin & Insertion Charts ... various sources on the principals of massage, anatomy , trigger points and ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... YORK , Feb. 23, 2017  Genesis Healthcare ... Company. The announcement was made by Bill Monast ... David Hartley and Nathan Feltman , executives ... Genesis Healthcare Services, LLC. This acquisition ... largest provider of technology enabled durable medical equipment (DME) ...
(Date:2/23/2017)... Feb. 23, 2017 Nevro Corp. (NYSE: NVRO), a ... for the treatment of chronic pain, today reported financial results ... 2016. 2016 Accomplishment & Highlights: ... 2016, an increase of 228% as reported, over the prior ... an increase of 612% over the prior year ...
(Date:2/23/2017)... , Feb. 23, 2017 Research and Markets ... and Strategies - 2016" report to their offering. ... The latest research Fibromyalgia ... and benchmarks in the global Fibromyalgia market. The research ... key drugs marketed for Fibromyalgia and their clinical attributes? How are ...
Breaking Medicine Technology: